PTD/S8/08a (07-09)
Approved for use through 07/31/2012, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid DMB control number

Substitute fo	or form 1449A/PTC	)		Complete if Known		
				Application Number	10/568,745	
	RMATION			Filing Date	02-21-06	
STAT	EMENT BY	Y AP	PLICANT	First Named Inventor	Mitsuko Ideno	
				Art Unit	1644	
0	Jse as many sheel	ts as nee	essary)	Examiner Name	Z. SKELDING	
Sheet	1	of	8	Attorney Docket Number	1422-0709PUS1	

			U.S. PATE	NT DOCUMENTS	
Examiner initial *	Cite No.	Document Number	Publication Date	Name of Patentee or	Pages, columns, Lines, Where
iliibai	NO.	Number - Kind Code <sup>2</sup> (if known)	Code <sup>2</sup> (If known) Applicant of Cited Document		Relevant Passages or Relevant Figures Appear
MIT STOCKHOOL	1	US-2003/0022210 - A1	01-30-2003	Bonyhadi et al.	
	2	US-2004/0101519 - A1	05-27-2004	June et al.	
	3	US-2005/227354 - A1	10-13-2005	Sagawa Hiroaki	
	4	US-6,472,204 - B1	10-29-2002	Asada et al.	
			1		

	FOREIGN PATENT DOCUMENTS							
	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, columns, Lines, Whe Relevant Passages or Releva			
Initial *	No. 1	Country <sup>3</sup> Number <sup>4</sup> Kind Code (if known) <sup>5</sup>	MM-DD-YYYY	Applicant of Cited Document	Figures Appear			
	5	WO 00/09168-A1	02-24-2000			[1]		
	6	WO 01/62895-A2	08-30-2001			11		
	7	WO 03/080817 - A1	02-10-2003					
	8	EP 0409655-A2	01-23-1991					
	9	EP 1424387 - A1	06-02-2004					
	10	EP 1666589 - A1	06-07-2006					

Examiner Signature		Date Considered					
* EXAMINER: In	* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not						

Considered Include copy of this form with next communication to applicant 1. Applicant's unique citation design number (optional), 2.5ee Kirok Cooke 4. WINFO platent Documents, at www.uspta.gov or MPEP 901.04. 3. Enter Office that issued the document, by the two letter code (WIPO Standard ST 3), 4. For Japanese patient documents, the indication of the year of the region of the Emperor must preced the section number of the patient document. 5. Kind of document by the experience spatient document as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to piace a check mark here if English language Translations as distinct.

This collection of Information is required by 37 CFR 137 and 138. The information is required to dotain or retain a benefit by the pacific which is to life (facind by the USPT) to process by application. Confidentifyi is powered by 35 US. C.12 and 37 CFR 14. This collection is esterated to lear be 2000 to complete, including pathering, preparing, and submitting the completed application from the USPTD. There will vary depending upon the individual case. Any comments on the amount of time, you require to complete his form and/or suppressions for reducing the burshes, should be served to the Cell information Office; U.S. Patent and Trademark Office, P.O. 80x 1459. Alexandria, V.A. 22313-1450. DO NOT SEND TEES ON COMPLETED FORMS TO THIS ADDRESS.

If you need assisstance in completing the form, call 1-800-PTO-9199 (1-800-786.9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/568,745	
INFORMATION DISCLOSURE				Filing Date	02-21-06	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Mitsuko Ideno	
				Art Unit	1644	
(U	lse as many she	ets as ne	cessary)	Examiner Name	Z. SKELDING	
Sheet	2	of	8	Attorney Docket Number	1422-0709PUS1	

U.S. PATENT DOCUMENTS							
Examiner initial *	er Cite Document Number		Publication Date	Name of Patentee or	Pages, columns, Lines, Where		
Initial -	No.	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear		
					·		
					·		
	-						
	ļ						
					i		
	<del> </del>				<b> </b>		

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initial *	Cite No. 1	Foreign Patent Document  Country <sup>3</sup> Number <sup>4</sup> Kind Code (if known) <sup>5</sup> Code  MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, When r Relevant Passages or Relevan Floures Appear	
	11	JP 2003-80817 - A	03-19-2003			П
	12	WO 2004-018667 - A1	03-04-2004			П
	13	WO 2005/019450 - A1	03-03-2005			m
	14	JP 3-284700-A	12-16-1991			П
	15	JP 3-80076-A	04-04-1991			П
	16	JP 5-271291-A	10-19-1993			П

Examiner Signature		Date Considered	
* EXAMINER: I	itial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thro	ough citation if not i	n conformance and not

Considered include copy of this form with next communication to applicant. I. Applicant's unique claimly design number (optional), 2 See Kinds Codes of LEGY 10 peter Designers it, always unique or MPP 90 th 0.4. Serve Office the sizes with occurrently the health code (MPD 5 dishords ST 3), 4 For Japanese patient documents, the indication of the year of the neign of the Emperor must procede the serial number of the patient document. S. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 1. 6 if possible. 6. Applicant is to place a check mark here if English language Translation is attacked.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the LEPTO a process) and positionate. Ordinatelyinity is growned by \$51.04. C.12 and 37 CFR 1.41. The collection is estimated to late \$P\$ collection including pathering, organizing, and submitting the completed application form the LEPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suppressors for producing the burden, should be earlied to the Cell referencies of CFR 1.01 and Trademan Office, P.O. Box 1450 Alexandria, VA 2231-1460, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TC: Commission for Patheria, P.O. Box 1450, 1450, 1450, 14231-1440.

If you need assissance in completing the form, call 1-800-PTO-9199 (1-800-786.9199) and select option 2.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## Complete if Known Substitute for form 1449A/PTO **Application Number** 10/568,745 INFORMATION DISCLOSURE Filing Date 02-21-06 STATEMENT BY APPLICANT First Named Inventor Mitsuko Ideno 1644 (Use as many sheets as necessary) Examiner Name Z. SKELDING Sheet 3 of 8 Attorney Docket Number 1422-0709PUS1

			U.S. PATENT	DOCUMENTS	
Examiner initial *	Cite	Document Number	Publication Date	Name of Patentee or	Pages, columns, Lines, Where
niuai -	No.	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initial *	Cite No. 1	Foreign Patent Document	Foreign Patent Document Publication Date		Pages, columns, Lines, When Relevant Passages or Relevan	
Iriigiai	No. 1 Country <sup>3</sup> Number <sup>4</sup> Kind Code (if known) <sup>5</sup> MM-DD-YYYY		Applicant of Cited Document	Figures Appear		
	17	WO 97/01194 - A1	01-09-1997			1
	18	WO 97/11694 - A1	04-03-1997			1
	19	WO 99/33863-A1	07-08-1999			T
						1
						T
						1

Examiner Signature		Date Considered	
* EXAMINER: In	nitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line thro	ough citation if not i	n conformance and not

Considered include copy of this form with next communication to applicant 1 supplicant's unique citation design number (optional), 2 See Kinds Coders ( USPTO patient Documents, at www.usping.ory or the PEP 901.04.3. Enter Office that issued the document, by the two-letter code (WMPO Standard ST.3), 4 For Japanese patient cocuments, the indication of the year of the riging of the Emperor must percede the serial number of the patient document. S. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 1.6 if possible. 6. Applicant is to place a check mont here if Emplish language Translation is statistical.

This collection of information is required by 37 CPR 1.57 and 1.88. The information is required to detain or retain a breefit by the public which is to 18 (and by the USPT to process) an application. Confederable by personed by \$5.00.C. 12 and 37 CPR 1.14 This collection is estimated to be 28 because to composite, including applicating, preparing any sub-intrip, the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you recept into complete this form and/or supplications for reducing the bloom, abundle to early to the Child Information Officer, U.S. Patent and Trademark Office, P.O. 80 x 1450 Alexandria, V.A. 2231-1460, DO NOT SIND TEES OR COMPLETED FORMS TO THIS ADDRESS. SIND TO: Commissions for Patents P.O. 80x 1450 Alexandria, V.A. 2231-1460.

Approved for use through 07/31/2012, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Demonstrate and other Act of 1006, an accessor are con-

Substitute for	Substitute for form 1449B/PTO			C	omplete if Known
INFO	INFORMATION DISCLOSURE			Application Number	10/568,745
				Filing Date	02-21-06
SIAII	STATEMENT BY APPLICANT			First Named Inventor	Mitsuko Ideno
ſU	se as many sheets a	s neces	sarv)	Art Unit	1644
,-	,		,	Examiner Name	Z. SKELDING
Sheet	4	of	8	Attorney Docket Number	1422-0709PUS1

			_
Examiner initial *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
	20	"Animal Cell Culture: A Practical Approach", Edited by R.I. Freshney, IRL Press, Oxford, Washington, D.C., 1986, pp. 26-41	L
	21	ANIMAL CELL CULTURE METHODS, edited by R. Freshney, Moscow, "Mir", 1989, pages 44, 53, 77 (the original English "Animal Cell Culture - A Practical Approach"), edited by R.I. Freshney, IRL Press, Oxford, Washington, D.C.	L
	22	BENIGNI, Febio et al.; Phenotype and Homing of CD4 Tumor-Specific T Cells is Modulated by Tumor Bulk; The Journal of Immunology; 2005, 175, pp. 739-748.	L
	23	DARDALHON et al., "Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector," Blood, Vol. 96, No. 3, 2000, pp. 885-893.	Ĺ
	24	FUNARO et al., "Stimulation of T Cells via CD44 Requires Leukocyte-Function-Associated Antigen Interactions and Interleukin-2 Production", Human Immunology, Vol. 40, 1994, pps. 297-278	Ľ
	25	GATTINONI et al., "Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+T cells," J. Clin. Invest., Vol. 115, No. 6, 2005, pp. 1616-1626.	E
	26	HALVORSON et al., "alpha4 and alpha5 integrins costimulate the CD3-dependent proliferation of fetal thymocytes," Cell. immunol., Vol. 199, No. 1, 1998, pp. 1-9.	Ē
	27	HIBINO et al., "Tenascin Suppresses CD3-Mediated T Cell Activation", Biochemical and Biophysical Research Communications, Vol. 250, 1998, pp. 119-124.	Ľ
	28	IDENO et al., "RetroNectin® Kumiawaseta T Saibo Kakudai Baiyo (II): Kakudai Baiyo sareta T Saibo Shadan wa NaiveT-yo Saibo no Hintus ng Takaku, Takai Kogen Nishikino o Hakki," Dai 65 Kai Annual Meeting of the Japan Cancor Assocation (kij. 2006, pp. 330.	С
	29	IDENO et al., "Soshikitai Human Fibronectin Fragment Shigeki ni yoru Kasseika CTL no Tairyo Expansion-ho," Dai 62 Kai Annual Meeting of the Japan Cancer Association Kiji, 2003, pp. 175.	L

Examiner Signature	Date Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

P.O. Box 1450 Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assisstance in completing the form, call 1-800-PTO-9199 and select option 2.

considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering. preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office,

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use through 07/31/2012. OMB 0651-0031

Substitute for	form 1449B/PTO			Complete if Known		
INFOE	MATION D	ISCI	OSLIDE	Application Number	10/568,745	
	EMENT BY			Filing Date	02-21-06	
SIAII	EMENIBI	AFF	LICANT	First Named Inventor	Mitsuko Ideno	
(u	se as manv sheets a	s neces	sarv)	Art Unit	1644	
,	,			Examiner Name	Z. SKELDING	
Sheet	5	of	8	Attorney Docket Number	1422-0709PUS1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner initial *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serlal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	30	International Search Report in International Application No. PCT/JP02/08298 mailed December 3, 2002	
	31	JPO International Search Report, Appl. No. PCT/JP2006/315881, October 10, 2006	Е
	32	JPO International Search Report, Appl. No. PCT/JP2008/319105, January 9, 2007	Ľ
	33	Kim YOUNG-JUNE et al., "4-18B Costimulation Promotes Human T Cell Adhesion to Fibronectin", Cellular Immunology 192, 13-23 (1999)	Ľ
	34	KOBERDA et al., "Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res. Clin. Oncol., vol. 119, 1993, pp. 131-138.	L
	35	MATSUYAMA et al., "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. 1133-1146.	L
		MIKAMO, "Bulk Culture of Human Lymphogytes", Coll Technology, 1905, 14:2, 223-227.	_
	36	Not in English Language	L
	37	MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988.	E
	38	MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association (Kij. 2006, pp. 350.	
	39	Office Action in Chinese Application No. 200480024172.7 malled January 15, 2010, including English translation.	Ľ
			İ

Examiner Signature	-	Date Considered	
* EXAMINER: Initial if re	ference considered, whether or not citation is in conformance with MPEP 609. Draw li	ne through citation	if not in conformance and not

P.O. Box 1450 Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assisstance in completing the form, call 1-800-PTO-9199 and select option 2.

considered. Include copy of this form with next communication to applicant,

Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTD

to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office,

Approved for use through 07/31/2012. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. OEPARTMENT OF COMMERCE

Und	Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.								
Substitute for	form 1449B/PTO			Complete if Known					
INFOE	MATION D	ISCI	OSLIDE	Application Number	10/568,745				
	EMENT BY			Filing Date	02-21-06				
SIAII	EMENT DI	AFF	LICANI	First Named Inventor	Mitsuko Ideno				
(U	se as many sheets a	s neces	sary)	Art Unit	1644				
				Examiner Name	Z. SKELDING				
Sheet	6	of	8	Attorney Docket Number	1422-0709PUS1				

Examiner nitial *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ;
	40	Office Action in Chinese Application No. 200480024172.7 mailed November 30, 2007, including English translation.	L
	41	RAO, W. H. et al, "Potent Costimulation of Effector T Lymphocytes by Human Collagen Type I," J Immunol, 2000, vol. 195, pp. 4935-4940	L
	42	Retronectin, 2010, Takara Bio. Inc., http://catalog.takara-bio.co.jp/en/PDFFiles/T100A_B_e.pdf.p.1-8	
	43	SAGAWA et al., "Ko-CD3 Kotal to RetroNectin??o Kurniawaseru Koto ni yoru LAK Salbo Inyu Ryoho no Kairyo," Dal 62 Kai Annual Meeting of the Japan Cancer Association Kiji," 2003, pp. 438.	Г
	44	SEKINE, "Expansion of Lymphocytes by Culture with immobilized Anti-CD3 Monoclonal Antibody and Interleukin-2 for Use in Adoptive Immunotherapy of Cancer Patients", Saibo Balyo (Cell Culture), Vol. 17, No. 6, 1991, pp. 192-195.	L
	45	SHUQIN et al., "induction of Allogenic Cytotoxic T Lymphocytes and Their Culture", Journal of South China Normal University (Natural Science Edition), No. 4, 1994, pp. 11-17 (including partial English language translation)	L
	46	SIMON, Markus M. et al., The outer surface lipoprotein A of Borrelia burgdorferi provides direct and indired augmenting/co-stimulatory signals for the activation of CD4+ and CD8+ T cells*, Immunol. Lett., 1995, Vol. 48, No. 3, pp. 137-142.	E
	47	STOHL et al., "Generation of Cytolytic Activity with Anti-CD3 Monoclonal Antibodies involves Both IL-2-Independent and -Dependent Components", J. Immunol., Vol. 144, No. 10, May 15, 1990, pp. 3716-3725	Ē
	48	STURM, A., et al. "Dual Function of the Extracellular Matrix: Stimulatory for Cell Cycle Progression of Naive T Cells and Authopoiotic for Tissue-Derived Memory T Cells," The Journal of Immunology, 2004, vol. 173, pp. 3889-3900	Ľ
	49	Supplementary European Search Report issued by the EPO in corresponding European Application No. 06782667.7 on September 16, 2009.	L

Examiner
Signature

\*EXAMINER hill if reference considered, whether or not citation is in conformance with MPEP 609. Graw then Provale datation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 GPM 1-97 and 1.58, The information is required to obtain or retain a benefit by the public which is to fifty when USPT to proceed by 39 GPM 1-97 and 1.58, The information is required to obtain or retain a benefit by the public which is to fill endined by the USPT or proceed by 39 GPM 1-97 and 1-

P.O. Box 1450 Alexandria, VA 22313-1450. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SENO TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

## Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449B/PTO **Application Number** 10/568.745 INFORMATION DISCLOSURE Filing Date 02-21-06 STATEMENT BY APPLICANT First Named Inventor Mitsuko Ideno Art Unit 1644 (Use as many sheets as necessary) Examiner Name Z. SKELDING Sheet 7 of 8 Attorney Docket Number 1422-0709PUS1

Examiner Cite Initial * No.1							
	50	TAKAYAMA et al., "Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial", The Lancet, Vol. 356, 2000, pp. 802-807	L				
	51	US Office Action for Application No. 10/344,534, dated November 6, 2009	L				
	52	US Office Action for Application No. 10/344,534, mailed May 13, 2008	E				
**************************************	53	US Office Action for Application No. 10/344,534, November 24, 2009	Ī				
	54	US Office Action for Application No. 10/486,512, dated June 25, 2004	Ī				
	55	US Office Action for Application No. 10/509,055, dated May 11, 2007					
	56	US Office Action for Application No. 10/509,055, mailed February 10, 2011					
	57	US Office Action, dated August 31, 2010, for US Application No. 11/990,443	L				
	58	US Office Action, dated December 28, 2010, for US Application No. 11/992,661	E				
	59	US Office Action, dated February 10, 2011, for US Application No. 10/509,055					

Examiner Signature	Date Considered	

<sup>\*</sup> EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assisstance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>1.</sup> Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to totalism or retain a benefit by the uptile which is to file (and by the USPTO to process) an application. Conferentially a speemed by 54 U.S. C. 22 and 37 CPR 1.41 Art is collection is estimated to blaze 2 hours to complete, including againstering preparing, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his time ander waggestors for reducing the bounds, and to be sent to the Certific information officers. J. Parter and Toffenders Officer.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for	r form 1449B/PTO			C	omplete if Known
INFO	RMATION D	ieci	OSLIDE	Application Number	10/568,745
	EMENT BY			Filing Date	02-21-06
SIAII	EMICIALIDI	AFF	LICANI	First Named Inventor	Mitsuko Ideno
(U	se as many sheets a	s neces	sarv)	Art Unit	1644
	(out as many should as housesary)				Z. SKELDING
Sheet	8	of	8	Attorney Docket Number	1422-0709PUS1

		NON PATENT LITERATURE DOCUMENTS	
Examiner initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, vidy ander ocurry where publisher.	Т
	60	US Office Action, dated July 6, 2011, for US Application No. 10/509,055	
	61	US Office Action, dated June 9, 2011, for US Application No. 11/992,661	Ĺ
	62	US Office Action, dated March 16, 2011, for US Application No. 11/990,443	Ĺ
	63	US Office Action, dated October 14, 2010, for US Application No. 11/992,661	C
	64	WHITESIDE et al., "Isolation of Human NK Cells and Generation of LAK Activity, Current Protocols in Immunology", 1996, Supp. 17, Unit 7.7, pages 7.7.1-7.7.11.	L
	65	WILLIAMS et al., "Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions," Letters to Nature, Vol. 352, 1991, pp. 438-441	L
	66	WILLS, M. R., et al. "Identification of Naive or Antigen-Experienced Human CD8+ T Cetls by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cetl Response," The Journal of Immunology, 2002, vol. 186, pp. 5455-546	L
	67	ZHOU et al., "Molecular Mechanisms Underlying Differential Contribution of CD28 Versus Non-CD28 Costimulatory Molecules to IL-2 Promoter Activation," The Journal of Immunology, Vol. 168, 2002, pp. 3847-3891	L

Examiner Signature	/Zachary Skelding/	Date Considered	08/30/2011					
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not								

considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with practical communication to application.

1. Applicants injure obtained seignation number, (opinional) 2. Applicants to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.